NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Outlook Therapeutics, Inc. (OTLK) Stock Analysis

Outlook Therapeutics, Inc. (OTLK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OTLK

$0.67

+$0.02 (+2.77%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OTLK with… →

OTLK Key Statistics

As of Sep 4, 2026
Trading
Open
$0.66
Previous Close
$0.65
Day's Range
0.65–0.70
52-Week Range
0.16–2.54
Volume
6.36M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$161.74M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.70
Financials (FY)
Revenue (FY)
$1.41M
Net Income (FY)
−$62.42M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
242.67M
1-Year Return
−24.89%
Dividend and dates
Avg Volume
17.75M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OTLK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−57.78%
2025−16.40%
2024−76.02%
2023−63.52%
2022−20.59%
2021+4.62%
2020+120.34%
2019−85.25%
2018−61.54%
2017−56.81%
2016 (partial year)−13.26%

As of September 4, 2026.

OTLK Revenue and Earnings by Fiscal Year

FY ends September
Fiscal yearRevenueNet incomeNet margin
2025$1.41M−$62.42M−4416.2%
2024$0.00−$75.37M—
2023$0.00−$58.98M—
2022$0.00−$66.05M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.41M$57.21K−$67.06M−$62.42M−4416.2%
2024$0.00$0.00−$71.70M−$75.37M—
2023$0.00—−$53.13M−$58.98M—
2022$0.00—−$63.07M−$66.05M—

Annual figures as reported, in the company's reporting currency. As of September 30, 2025.

OTLK Valuation vs Biotechnology Median

Median of 656 stocks
MetricOTLKBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Outlook Therapeutics, Inc. (OTLK) at $161.74M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 17 employees.

Over the past 52 weeks the price has ranged from $0.16 to $2.54. The most recent close on file for OTLK is $0.67, dated September 4, 2026. That is +$0.02 (+2.77%) against the previous close. The latest close sits 314.29% above that 52-week low.

Financial Health

In fiscal 2025, Outlook Therapeutics, Inc. reported revenue of $1.41M. The same year closed with a net loss of $62.42M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.7.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $1.41M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 0.75. Daily returns over the trailing 10 years annualize to a volatility of 123.77%. Over the trailing twelve months the price has returned −24.89%. Measured over 10 years, that is −50.53% a year compounded.

Growth & Income

No dividend is on file for OTLK.

The strongest complete calendar year on file is 2020 at +120.34%; the weakest is 2019 at −85.25%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −57.78%.

Peer Comparison

Outlook Therapeutics, Inc. (OTLK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Outlook Therapeutics, Inc. OTLK $161.74M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Outlook Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Visit website →